NCT04222322已完成不适用
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity With and Without Prediabetes
Epitomee medical18 个研究点 分布在 1 个国家目标入组 279 人开始时间: 2020年9月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 279
- 试验地点
- 18
- 主要终点
- The proportion of treatment responders in the active group
研究概览
简要总结
The effect of Epitomee Capsule on body weight in patients with overweight and obesity with and without Prediabetes
详细描述
This is a Prospective, Randomized, Double-blind, Placebo controlled, Multi-center, Pivotal, Adaptive trial designed to demonstrate that the use of Epitomee Capsule, in combination with lifestyle modification, is superior to the placebo device in reducing body weight at 24-weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women >= 18 years
- •Current BMI of 25.0-40.0 kg/m2 inclusive
- •Eligible female subjects will be:
- •Non-pregnant, evidenced by a negative urine dipstick pregnancy test Non-lactating Females will be either surgically sterile or postmenopausal or agree to continue using an accepted method of birth control during the study.
- •Normoglycemic subjects with both:
- •Fasting plasma glucose <100 mg/dL
- •HbA1c <5.7% or:
- •Prediabetic subjects with either one or both of the following criteria:
- •FPG≥100 mg/dL and <126 mg/dL
- •5.7% ≤ HbA1c ≤6.4% Naive Prediabetes or treated with metformin (up to 2000mg/dL inclusive)
- •Ability to provide informed consent before any trial-related activities
- •Ability and willingness to complete the physical activity in accordance to the study's exercise program
- •Willingness to maintain a diet in accordance with study requirement for the duration of the study
- •Subjects must have:
- •A primary care provider who is responsible for providing routine care
- •A reliable telephone or internet service to communicate with study staff
- •Understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent
- •Study subjects must be willing to notify the staff of any change in their medical health (including surgeries) or change in drug treatments (addition of drugs, stopping of drugs, or change in drug dose) during the course of the trial.
- •Previously attempted to lose weight unsuccessfully using a medically supervised or self-directed diet.
- •Willingness to avoid medications or other substances known to affect weight changes during the study
- •Willingness to avoid non-steroidal anti-inflammatory drugs (NSAIDs) other than low dose aspirin including Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric irritants during the study.
- •Subjects on psychiatric medications are clinically well-controlled with a stable psychiatric medication dose for at least 3 months prior to study entry.
排除标准
- •Pregnant or nursing, or plans to become pregnant in the next 12 months, or not using adequate contraceptive measures
- •Weight loss of more than 10 pounds in the past 6 months
- •Use in the past 6 months of medications or other substances known to induce weight gain or weight loss
- •Participation in any clinical study (weight-loss or non-weight loss study) within the past 3 months
- •Known history of endocrine disorders affecting weight, such as uncontrolled abnormal thyroid function, hypothalamic tumors, Cushing's syndrome, or other genetic syndromes
- •Currently receiving chronic steroid or immunosuppressive therapy
- •Subjects previously diagnosed with HIV, hepatitis B or C
- •Subjects diagnosed with bulimia, binge eating disorder, compulsive overeating, high liquid calorie intake, or similar eating related psychological disorders
- •Intent to undergo gastric surgery or gastric banding during the study period or within the 6-month period after completion of this study
- •Prior use of any weight loss gastric medical device such as gastric balloon or gastric aspiration device
- •Known history of structural or functional disorders of the esophagus that may impede passage of the device through the gastrointestinal tract, including: Barrett's esophagus, esophagitis, dysphagia, achalasia, stricture/stenosis, esophageal varices, esophageal diverticula, esophageal perforation, or any other disorder of the esophagus
- •Known history of any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms
- •Known history of structural or functional disorders of the stomach including, gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (> 2 cm), cancer or any other disorder of the stomach or any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety.
- •Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract
- •Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting
- •Known history of irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease
- •Known history of GI surgeries that may have resulted in anatomical GI tract abnormalities such as a stoma, Nissen Fundoplication or narrowing of any portion of the digestive tract. Examples of these GI surgeries include, but are not limited to, gastric banding; however, uncomplicated appendectomies are acceptable. In addition, known history of any surgeries that may have resulted in anatomical GI tract abnormalities such intestinal adhesions, or any other condition that may inhibit passage through any portion of the GI tract must be excluded
- •Subjects with Type 1 diabetes or type 2 diabetes
- •Experienced a myocardial infarction, has a known history of angina, underwent coronary bypass, a known history of congestive heart failure, or is currently being medically treated for any other cardiac condition
- •Poorly controlled hypertension (≥ 160 mmHg systolic and ≥ 100mmHg diastolic)
- •End stage renal disease or requiring hemodialysis within the past 6 months
- •Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications
- •Subjects requiring the use of anti-platelet drugs (except for low dose Aspirin as mentioned above) or other agents affecting the normal clotting of blood
- •Study subjects must not have a history of substance use disorder (licit or illicit) drug or alcohol abuse/addiction within 5 years of visit #1 (i.e. day of signing the informed consent document).
- •Study subjects must not have a medical history of sensitivity, intolerance, or toxicity to the investigational product, or agents similar to the investigational product.
- •Study subjects must not have a history of anaphylaxis or anaphylactoid reaction to any prior drug or supplement of any kind.
- •Study subjects must not have a history of cancer with the exception of non-melanoma skin cancer and "in situ" cancer of the cervix.
- •Study subjects must not be anticipating a significant change in job, job duties, or job work hours, which might impair their ability and willingness to undergo study-related procedures under the timelines specified by protocol, and otherwise impede their completion of the study.
- •Study subjects must not anticipate a reasonable likelihood of moving away from the research site, wherein such a move might impair their ability and willingness to undergo study-related procedures within the timelines specified by protocol, or otherwise impede their completion of the study.
- •Subjects who stopped smoking within 6 months prior to Screening Visit or considering smoking cessation during the study
- •Subjects who are habitual laxative users or using prescription medication for chronic constipation
- •Study subjects must not have change in medications treating hypertension and/or dyslipidemia within 1 month prior to Screening Visit (including change in dose)
- •Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition.
- •Subject is employed by the investigator, or is a close relative of the investigator, or the investigator's staff
- •Subject is a close relative of another subject already enrolled in the study or lives in the same home with another subject enrolled in the study.
- •Subjects on psychiatric medications with no lifetime history of suicidal behavior.
- •Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psycho-social issues).
研究组 & 干预措施
Epitomee Capsule
Experimental
Epitomee Capsule combined with moderate intensity lifestyle counseling
干预措施: Epitomee Capsule (Device)
Control-Placebo
Placebo Comparator
Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling
干预措施: Control-Placebo (Other)
结局指标
主要结局
The proportion of treatment responders in the active group
时间窗: 24 weeks
The proportion of treatment responders defined as subjects who have lost 5% or more of baseline weight at 24-weeks post randomization, among the active group
The difference between the percent body weight loss between the active and control groups
时间窗: 24 weeks
The difference between the percent average body weight loss at 24-weeks post randomization between the active and control groups
次要结局
未报告次要终点
研究者
研究点 (18)
Loading locations...
相似试验
已完成
不适用
The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)Overweight and ObesityNCT04994769Epitomee medical33
已完成
不适用
Effects of Palatinose™ on Weight Management and Body CompositionOverweight and ObesityDiet ModificationBody WeightNCT03652207Beneo-Institute64
进行中（未招募）
不适用
Effect of liraglutide on body weight in obese subjects without diabetes. A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an open label orlistat comparator arm with an 84 week extension periodTrial Phase:2bMedDRA version: 9.0Level: PTClassification code 10012601obesityEUCTR2006-004481-13-BEovo Nordisk A/S
进行中（未招募）
不适用
Effect of liraglutide on body weight in obese subjects without diabetesA 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an open label orlistat comparator armTrial Phase:2bMedDRA version: 9.0Level: PTClassification code 10012601obesityEUCTR2006-004481-13-NLovo Nordisk A/S547
进行中（未招募）
不适用
Effect of liraglutide on body weight in obese subjects without diabetes. A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an open label orlistat comparator arm with an 84 week extension periodTrial Phase:2bobesityEUCTR2006-004481-13-CZovo Nordisk A/S547